NCT01446952View on ClinicalTrials.gov

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

April 30, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Vitamin E δ-Tocotrienol

The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

BioGene Life Science
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

BioGene Life Science

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER